The TCA cycle, also known as the citric acid cycle or Krebs cycle, plays a fundamental role in cellular metabolism, primarily within the mitochondria. In normal cellular physiology, it is responsible for the oxidative metabolism of carbohydrates, fats, and proteins, facilitating energy production in the form of ATP. However, in the context of cancer, alterations in these metabolic pathways have been known to give rise to oncometabolites—compounds that promote tumorigenesis. This study delves into the mechanisms by which these metabolites influence both cancer cells and the immune cells that interact with them.

Oncometabolites such as 2-hydroxyglutarate (2-HG), fumarate, and succinate have been identified as byproducts of aberrant TCA cycle metabolism and are linked to specific mutations commonly found in various cancers. For instance, the IDH1 and IDH2 mutations that yield 2-HG are prevalent in gliomas and acute myeloid leukemia. 2-HG is thought to act as an oncometabolite by inhibiting α-ketoglutarate-dependent dioxygenases, which leads to epigenetic changes that promote oncogenesis. Understanding the intricate biochemical pathways that lead to the production of such metabolites provides vital insights into how we may target these processes therapeutically.

Furthermore, the interplay between oncometabolites and the immune microenvironment reveals a fascinating layer to cancer biology. Tumors are not isolated entities; instead, they exist within a complex network of immune cells that can either inhibit or promote cancer progression. For example, fumarate accumulation can lead to the activation of the transcription factor Nrf2, which has been shown to enhance the survival and function of regulatory T cells (Tregs). These immune cells can suppress anti-tumor responses, thereby creating an environment where cancer can thrive. This dynamic highlights the importance of metabolic interactions in shaping the immune landscape surrounding tumors.

Sarkar et al. also discuss the role of succinate in modulating immune responses. Elevated succinate levels are known to stabilize hypoxia-inducible factors (HIFs), which can promote the expression of pro-inflammatory cytokines that further influence immune cell behavior. The ability of succinate to impact both tumor metabolism and immune signaling underscores the potential of targeting metabolic pathways not only for direct anti-cancer strategies but also for reprogramming immune responses against tumors.

As we delve deeper into the implications of these findings, one must consider the potential therapeutic avenues that arise from manipulating TCA cycle-derived oncometabolites. The development of inhibitors against the enzymes responsible for these metabolic changes, such as IDH inhibitors, has already shown promise in clinical settings. These therapies not only target the metabolic dysregulation inherent in cancer cells but they also seek to restore normal immune function by altering the metabolic landscape within the tumor microenvironment.

Moreover, the idea of combining metabolic therapies with immunotherapies is particularly enticing. By reprogramming the metabolic state of tumors, we may enhance the efficacy of existing immune checkpoint inhibitors, creating a dual approach that targets both the cancer cell and its supportive immune environment. This kind of innovative thinking may usher in a new era of cancer treatment that prioritizes metabolic health alongside conventional therapeutic strategies.

The researchers also point out that understanding the metabolic profiling of tumors can serve as a predictive biomarker for patient outcomes. The presence and levels of specific oncometabolites could potentially guide therapeutic decisions, allowing for a more personalized approach to cancer treatment. This approach aligns with the growing field of precision medicine, where treatments are tailored to the individual characteristics of each patient’s tumor.

In conclusion, the research conducted by Sarkar and colleagues significantly advances our understanding of the role of TCA cycle-derived oncometabolites in cancer and the immune microenvironment. These findings illuminate the complex interplay between metabolism and immunology, laying the foundation for novel therapeutic strategies that can transform the cancer treatment landscape. As we continue to unravel these metabolic mysteries, the potential for improved patient outcomes grows, shaping a future in which cancer is not merely treated, but effectively managed and potentially eradicated.

The exploration of these pathways is a promising endeavor in the quest for more effective, less toxic cancer therapies. By leveraging our understanding of metabolism, we can begin to envision a comprehensive strategy that encompasses modulation of both the tumor and the immune system, fundamentally altering the trajectory of cancer treatment for years to come.

Subject of Research: TCA cycle-derived oncometabolites in cancer and the immune microenvironment.

Article Title: TCA cycle-derived oncometabolites in cancer and the immune microenvironment.

Article References:

Sarkar, S., Chang, CI., Jean, J. et al. TCA cycle-derived oncometabolites in cancer and the immune microenvironment.
J Biomed Sci 32, 87 (2025). https://doi.org/10.1186/s12929-025-01186-y

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s12929-025-01186-y

Keywords: TCA cycle, oncometabolites, cancer metabolism, immune microenvironment, metabolic therapy, precision medicine.

Gastric cancer remains one of the leading causes of cancer-related mortality worldwide, with therapeutic options often limited by tumor heterogeneity and resistance mechanisms. Immune checkpoint inhibitors (ICIs), particularly antibodies targeting programmed death-1 (PD-1) and its ligand PD-L1, have revolutionized treatment paradigms across multiple cancer types. However, their efficacy in gastric cancer has displayed considerable variability. The impact of comorbid viral infections like HBV on ICI responsiveness, until now, has been uncertain.

This study meticulously analyzed clinical data from 89 gastric cancer patients treated with anti-PD-(L)1 therapies. Crucially, patients were stratified into three distinct cohorts based on HBV infection status: those with chronic hepatitis B infection (13 patients), those with resolved hepatitis B infection (49 patients), and individuals without evidence of HBV infection (27 patients). Such stratification enabled a direct comparison of immunotherapy outcomes relative to viral status, a factor often overlooked in previous oncological trials.

Remarkably, the overall response rate (ORR) and disease control rate (DCR) observed under anti-PD-(L)1 therapy showed no statistically significant differences across the three patient groups. This finding suggests that the initial tumor responsiveness does not differ substantially due to HBV infection status. However, deeper survival analyses unravel a more compelling narrative regarding progression-free survival (PFS) and overall survival (OS).

In patients harboring chronic HBV infection, progression-free survival times were significantly extended compared to both HBV-uninfected and resolved HBV patients. Specifically, median PFS in CHB patients was not reached during the study period, in stark contrast to 7 months and 6 months in HBV-negative and resolved HBV cohorts, respectively. These differences were statistically significant, with hazard ratios indicating a roughly 60-70% reduction in the risk of disease progression among CHB patients receiving anti-PD-(L)1 therapy.

Similarly, overall survival outcomes favored the CHB cohort. Median OS was not reached in these patients, whereas it was 15 and 16 months in HBV-negative and resolved HBV groups, respectively. The data underscore a robust survival advantage linked to chronic hepatitis B infection within this immunotherapeutic context, hinting at a fundamental biological mechanism modulating treatment efficacy.

The observed survival benefits in CHB patients are hypothesized to originate from alterations in the tumor immune microenvironment imposed by persistent HBV infection. Chronic viral infections can induce a state of immune activation and inflammation, leading to a more “inflamed” or immunologically active tumor milieu. This environment likely enhances antigen presentation and immune cell infiltration, prime conditions for ICIs to exert maximal therapeutic effects by reinvigorating exhausted T cells.

Moreover, the lack of increased severe adverse events across all groups indicates that anti-PD-(L)1 therapy maintains a favorable safety profile, even in patients with chronic viral hepatitis. This is a crucial consideration since viral infections often raise concerns about immune-related toxicity or viral reactivation during immune modulation therapies.

These findings challenge prevailing assumptions that chronic viral infections might complicate or diminish the efficacy of immunotherapies in cancer. Instead, they highlight that chronic HBV infection could paradoxically sensitize tumors to immune checkpoint blockade, potentially through sustained immunological crosstalk and microenvironmental changes.

The translational implications of this study are profound. First, stratifying gastric cancer patients based on HBV status could become an essential aspect of personalized oncology, guiding treatment selection and prognosis. Second, the insights gained into the immunological dynamics introduced by HBV infection pave the way for novel combinatory approaches, perhaps integrating antiviral therapies with immunotherapy to maximize clinical benefit.

Further mechanistic studies will be crucial to delineate the precise immune pathways modulated by HBV in the gastric tumor microenvironment. Understanding these could unlock new biomarkers for predicting ICI responsiveness and offer targets for novel immunomodulatory agents.

In the broader context, this research underscores the importance of considering viral infections in cancer immunotherapy trials and practice. Given the global prevalence of HBV and the burden of gastric cancer, integrating viral status assessment into clinical protocols could substantially enhance patient outcomes.

The evolution of immune checkpoint inhibitors as a mainstay in cancer therapy continues to unveil unanticipated dimensions of tumor-immune interactions. This study contributes a remarkable piece to that puzzle, showcasing how a chronic viral infection, typically viewed as a complicating comorbidity, might instead amplify immunotherapy effectiveness.

From a clinical standpoint, these findings advocate for the safety and efficacy of deploying anti-PD-(L)1 agents in gastric cancer patients with concomitant chronic hepatitis B. It encourages oncologists and hepatologists to collaborate closely when managing such complex cases, ensuring multidisciplinary approaches to monitoring and treatment.

Future research efforts may also explore whether similar patterns exist in other HBV-associated malignancies or in cancers linked with other chronic viral infections, such as hepatitis C or human papillomavirus (HPV). The concept that viral-induced immune modulation enhances checkpoint inhibitor responsiveness could be a universal phenomenon, broadening the horizon of immuno-oncology.

In conclusion, the intersection of chronic hepatitis B infection and gastric cancer presents a unique immunological landscape that anti-PD-(L)1 therapy can effectively exploit. This paradigm highlights the dynamic interplay between infectious diseases and cancer, advocating a more integrated view of patient biology in the era of precision medicine. As immunotherapeutic modalities advance, incorporating viral infection parameters promises to refine and optimize treatment algorithms, ultimately improving survival and quality of life for patients worldwide.

Subject of Research:
Efficacy and safety of immune checkpoint inhibitors (anti-PD-(L)1 therapy) in gastric cancer patients with different hepatitis B virus infection statuses.

Article Title:
Anti-PD-1 therapy achieves favorable outcome in gastric cancer combined with chronic hepatitis B.

Article References:
Wang, L., Yang, F., Dong, Q. et al. Anti-PD-1 therapy achieves favorable outcome in gastric cancer combined with chronic hepatitis B. BMC Cancer 25, 1354 (2025). https://doi.org/10.1186/s12885-025-14776-8

Image Credits: Scienmag.com

DOI:
https://doi.org/10.1186/s12885-025-14776-8